Zimmer Biomet (ZBH) Given a $135.00 Price Target at Oppenheimer

Zimmer Biomet (NYSE:ZBH) has been assigned a $135.00 price target by Oppenheimer in a report released on Monday. The brokerage currently has a “buy” rating on the medical equipment provider’s stock. Oppenheimer’s price target suggests a potential upside of 17.82% from the stock’s current price.

A number of other research firms have also issued reports on ZBH. Canaccord Genuity increased their price target on Zimmer Biomet from $122.00 to $125.00 and gave the company a “hold” rating in a research report on Monday, July 30th. Citigroup increased their price target on Zimmer Biomet from $117.00 to $128.00 and gave the company a “neutral” rating in a research report on Tuesday, July 31st. Robert W. Baird increased their price target on Zimmer Biomet from $121.00 to $132.00 and gave the company a “neutral” rating in a research report on Monday, July 30th. Barclays started coverage on Zimmer Biomet in a research report on Monday, October 15th. They issued an “underweight” rating and a $131.00 price target on the stock. Finally, Cantor Fitzgerald increased their price target on Zimmer Biomet from $140.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday, July 30th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $133.86.

ZBH opened at $114.58 on Monday. Zimmer Biomet has a 12-month low of $104.28 and a 12-month high of $134.55. The company has a current ratio of 1.89, a quick ratio of 0.96 and a debt-to-equity ratio of 0.70. The stock has a market cap of $23.43 billion, a P/E ratio of 14.27, a PEG ratio of 2.11 and a beta of 1.08.



Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.03. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The firm had revenue of $1.84 billion for the quarter, compared to analyst estimates of $1.84 billion. During the same quarter in the prior year, the company earned $1.72 EPS. Zimmer Biomet’s revenue was up 1.3% on a year-over-year basis. Equities analysts forecast that Zimmer Biomet will post 7.66 earnings per share for the current year.

In other Zimmer Biomet news, CEO Bryan C. Hanson bought 410 shares of the business’s stock in a transaction dated Friday, August 31st. The shares were acquired at an average price of $123.03 per share, with a total value of $50,442.30. Following the transaction, the chief executive officer now owns 25,487 shares of the company’s stock, valued at $3,135,665.61. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Chad F. Phipps sold 30,100 shares of the firm’s stock in a transaction dated Friday, September 21st. The stock was sold at an average price of $132.37, for a total value of $3,984,337.00. The disclosure for this sale can be found here. 0.71% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Flinton Capital Management LLC raised its position in shares of Zimmer Biomet by 8.0% during the 2nd quarter. Flinton Capital Management LLC now owns 12,444 shares of the medical equipment provider’s stock worth $1,387,000 after acquiring an additional 918 shares in the last quarter. Schroder Investment Management Group grew its stake in Zimmer Biomet by 71.5% during the 2nd quarter. Schroder Investment Management Group now owns 64,996 shares of the medical equipment provider’s stock worth $7,233,000 after buying an additional 27,096 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Zimmer Biomet by 0.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 957,471 shares of the medical equipment provider’s stock worth $106,700,000 after buying an additional 7,733 shares during the last quarter. Legal & General Group Plc grew its stake in Zimmer Biomet by 2.3% during the 2nd quarter. Legal & General Group Plc now owns 983,726 shares of the medical equipment provider’s stock worth $109,634,000 after buying an additional 21,825 shares during the last quarter. Finally, HPM Partners LLC grew its stake in Zimmer Biomet by 29.3% during the 2nd quarter. HPM Partners LLC now owns 13,241 shares of the medical equipment provider’s stock worth $1,476,000 after buying an additional 3,001 shares during the last quarter. 86.58% of the stock is currently owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Read More: What is Considered a Good Return on Equity (ROE)?

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply